Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

FHS
May 16, 2024
12:09 pm

Closed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced the initiation of their OptiZest study, ID: NCT06372470, and first patient recruitment.

Annual forecast raised again – Biotech Investments

Drägerwerk AG & Co. KGaA / Key word(s): Change in Forecast Drägerwerk AG & Co. KGaA: Annual forecast raised again 13-Dec-2023 / 18:41 CET/CEST Correction

December 14, 2023

RP-12146 by Rhizen Pharmaceuticals for Gastric Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

June 19, 2024

Merck and Eisai to stop Keytruda plus Lenvima trial in head and neck cancer after disappointing interim results

Merck and Eisai announced Friday morning that they plan to close a Phase III study of the combination of Keytruda and Eisai’s tyrosine kinase inhibitor

August 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.